Early phase II study of mixed 19‐peptide vaccine monotherapy for refractory triple‐negative breast cancer

We undertook an early phase II study of mixed 19‐peptide cancer vaccine monotherapy for 14 advanced metastatic triple‐negative breast cancer (mTNBC) patients refractory to systemic chemotherapy to develop a new type of cancer vaccine. The treatment protocol consisted of a weekly vaccination for 6 we...

Descripción completa

Detalles Bibliográficos
Autores principales: Toh, Uhi, Sakurai, Sayaka, Saku, Shuko, Takao, Yuko, Okabe, Mina, Iwakuma, Nobutaka, Shichijo, Shigeki, Yamada, Akira, Itoh, Kyogo, Akagi, Yoshito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419019/
https://www.ncbi.nlm.nih.gov/pubmed/32495455
http://dx.doi.org/10.1111/cas.14510

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419019/
https://www.ncbi.nlm.nih.gov/pubmed/32495455
http://dx.doi.org/10.1111/cas.14510

Ejemplares similares